Ligand Pharmaceuticals (LGND) Non-Current Receivables (2017 - 2025)
Historic Non-Current Receivables for Ligand Pharmaceuticals (LGND) over the last 4 years, with Q3 2025 value amounting to $206.3 million.
- Ligand Pharmaceuticals' Non-Current Receivables rose 355.38% to $206.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.3 million, marking a year-over-year increase of 355.38%. This contributed to the annual value of $185.0 million for FY2024, which is 19703.17% up from last year.
- Per Ligand Pharmaceuticals' latest filing, its Non-Current Receivables stood at $206.3 million for Q3 2025, which was up 355.38% from $193.6 million recorded in Q2 2025.
- Ligand Pharmaceuticals' 5-year Non-Current Receivables high stood at $206.3 million for Q3 2025, and its period low was $62.3 million during Q4 2023.
- Moreover, its 3-year median value for Non-Current Receivables was $186.7 million (2024), whereas its average is $147.6 million.
- As far as peak fluctuations go, Ligand Pharmaceuticals' Non-Current Receivables skyrocketed by 19703.17% in 2024, and later surged by 355.38% in 2025.
- Quarter analysis of 3 years shows Ligand Pharmaceuticals' Non-Current Receivables stood at $62.3 million in 2023, then skyrocketed by 197.03% to $185.0 million in 2024, then grew by 11.52% to $206.3 million in 2025.
- Its last three reported values are $206.3 million in Q3 2025, $193.6 million for Q2 2025, and $188.3 million during Q1 2025.